Shandong University of Traditional Chinese Medicine, Jinan, China.
Diabetes Metab Res Rev. 2024 Sep;40(6):e3839. doi: 10.1002/dmrr.3839.
Gestational diabetes mellitus (GDM) has a strong genetic predisposition. Integrating metabolomics with Mendelian randomisation (MR) analysis offers a potent method to uncover the metabolic factors causally linked to GDM pathogenesis.
This study aims to identify specific metabolites and metabolic pathways causally associated with GDM susceptibility through a comprehensive MR analysis. Additionally, it seeks to explore the potential of these identified metabolites as circulating biomarkers for early GDM detection and risk assessment. Furthermore, it aims to evaluate the implicated metabolic pathways as potential therapeutic targets for preventive or interventional strategies against GDM.
A two-sample MR study was conducted using summary statistics from a metabolite genome-wide association study (GWAS) of 8299 individuals and a GDM GWAS comprising 13,039 cases and 197,831 controls. Rigorous criteria were applied to select robust genetic instruments for 850 metabolites.
MR analysis revealed 47 metabolites exhibiting putative causal associations with GDM risk. Among these, five metabolites demonstrated statistically significant associations after multiple-testing correction: Beta-citrylglutamate, Isobutyrylcarnitine (c4), 1,2-dilinoleoyl-GPC (18:2/18:2), Alliin and Cis-3,4-methyleneheptanoylcarnitine. Importantly, all these metabolites exhibited protective effects against GDM development. Additionally, metabolic pathway enrichment analysis implicated the methionine metabolism and spermidine and spermine biosynthesis pathways in the pathogenesis of GDM.
This comprehensive MR study has robustly identified specific metabolites and metabolic pathways with causal links to GDM susceptibility. These findings provide novel insights into the metabolic underpinnings of GDM aetiology and offer promising translational implications. The identified metabolites could serve as potential circulating biomarkers for early detection and risk stratification, while the implicated metabolic pathways may represent therapeutic targets for preventive or interventional strategies against GDM.
妊娠糖尿病(GDM)具有很强的遗传易感性。将代谢组学与孟德尔随机化(MR)分析相结合,提供了一种强大的方法来发现与 GDM 发病机制因果相关的代谢因素。
本研究旨在通过全面的 MR 分析,确定与 GDM 易感性因果相关的特定代谢物和代谢途径。此外,还探讨了这些鉴定出的代谢物作为早期 GDM 检测和风险评估的潜在循环生物标志物的可能性。此外,还评估了所涉及的代谢途径作为针对 GDM 的预防或干预策略的潜在治疗靶点的潜力。
使用来自 8299 个人的代谢物全基因组关联研究(GWAS)和包含 13039 例病例和 197831 例对照的 GDM GWAS 的汇总统计数据,进行了两样本 MR 研究。应用严格的标准为 850 种代谢物选择稳健的遗传工具。
MR 分析显示,47 种代谢物与 GDM 风险具有潜在因果关系。其中,在经过多次测试校正后,有 5 种代谢物表现出统计学上显著的关联:Beta-citrylglutamate、Isobutyrylcarnitine(c4)、1,2-dilinoleoyl-GPC(18:2/18:2)、Alliin 和 Cis-3,4-methyleneheptanoylcarnitine。重要的是,所有这些代谢物均对 GDM 的发生具有保护作用。此外,代谢途径富集分析表明,GDM 发病机制中涉及蛋氨酸代谢和亚精胺和精胺生物合成途径。
本项全面的 MR 研究稳健地确定了与 GDM 易感性因果相关的特定代谢物和代谢途径。这些发现为 GDM 发病机制的代谢基础提供了新的见解,并为早期检测和风险分层提供了有前景的转化意义。鉴定出的代谢物可能成为早期检测和风险分层的潜在循环生物标志物,而所涉及的代谢途径可能代表针对 GDM 的预防或干预策略的治疗靶点。